| __timestamp | Iovance Biotherapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 3243000 |
| Thursday, January 1, 2015 | 999000 | 2472000 |
| Friday, January 1, 2016 | 978000 | 2548000 |
| Sunday, January 1, 2017 | 952000 | 19623000 |
| Monday, January 1, 2018 | 956000 | 30421000 |
| Tuesday, January 1, 2019 | 8122999 | 32793999 |
| Wednesday, January 1, 2020 | 8712000 | 28304000 |
| Friday, January 1, 2021 | 13980000 | 620000 |
| Saturday, January 1, 2022 | 21135000 | 755000 |
| Sunday, January 1, 2023 | 10755000 | 1322000 |
Cracking the code
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. Iovance Biotherapeutics, Inc. and Viridian Therapeutics, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Iovance's cost of revenue surged by approximately 125% from 2014 to 2022, peaking in 2022 before a slight decline in 2023. In contrast, Viridian experienced a dramatic rise in costs, with a peak in 2019, where costs were over 10 times higher than in 2014. However, by 2023, Viridian's costs had plummeted by nearly 96% from their 2019 peak. These trends highlight the volatile nature of the biotech industry, where strategic shifts and market dynamics can significantly impact financial outcomes. Investors should consider these patterns when evaluating the financial health and strategic direction of these companies.
Cost of Revenue Trends: AbbVie Inc. vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Merck & Co., Inc. and Viridian Therapeutics, Inc.'s Expenses
Amgen Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Cost of Revenue Trends: Catalent, Inc. vs Viridian Therapeutics, Inc.
Cost of Revenue Comparison: Walgreens Boots Alliance, Inc. vs Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: PTC Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Wave Life Sciences Ltd.
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Evotec SE and Viridian Therapeutics, Inc.